Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer

Completed

• Conditions: Bladder Cancer

• Registration Number: NCT03125460
• Lead Sponsor: Cepheid

Brief Summary

The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-12
• Study First Submitted: 2017-04-17
• Study First Submitted QC: 2017-04-19
• Study First Posted: 2017-04-24
• Primary Completion: 2019-02
• Study Completion: 2019-05
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-06
• Last Update Posted: 2020-02-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 424

Inclusion Criteria

• Subject is ≥ 40 years of age
• Subject has provided documented informed consent as required by the reviewing IRB or EC. Experimental Bill of Rights will be documented for all subjects enrolled in applicable states.
• Subject is considered disease positive within 12 months (365 days) of enrollment.
• At the time of the enrollment visit, the subject is scheduled for a standard of care cystoscopy which will be completed within 3 days of providing a urine specimen.
• Subject has agreed to provide at least 60 mL of voided urine for study purposes at the enrollment visit.
• Subject has agreed to provide at least 60 mL of voided urine for study purposes at each subsequent standard of care cystoscopy visit for at least 12 months (365 days) following enrollment if the subject will enter the Longitudinal cohort.
• Any subject considered anticipatory positive at the initial visit shall be enrolled into the longitudinal cohort. For each anticipatory positive enrolled into the longitudinal cohort a random disease negative subject shall be enrolled.

Exclusion

• Subject has been previously enrolled into the study.
• Urine specimen to be used for study purposes is from the first morning void.
• Subject has had an excision procedure within six weeks (42 days) of enrollment.
• The subject is not scheduled for a standard of care cystoscopy visit within 12 months (365 days) following enrollment.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison to histology for positive or suspicious cystoscopy	Follow up = 12 months from Subject Enrollment (Baseline)	Comparison to histology for positive or suspicious cystoscopy

Secondary Outcome Measures

Name	Time	Method
Comparison to UroVysion and urine cytology	Follow up = 12 months from Subject Enrollment (Baseline)	Urovysion and urine cytology

Trial Locations

Locations (17)

PAVA; 🇺🇸 Palo Alto, California, United States

The Urology Center of Colorado, P.C.; 🇺🇸 Denver, Colorado, United States

Urology Associates, P.C.; 🇺🇸 Englewood, Colorado, United States

North Idaho Urology; 🇺🇸 Coeur d'Alene, Idaho, United States

Idaho Urologic Institute; 🇺🇸 Meridian, Idaho, United States

UroPartners; 🇺🇸 Melrose Park, Illinois, United States

Five Valleys Urology; 🇺🇸 Missoula, Montana, United States

Weill Cornell Medicine; 🇺🇸 New York, New York, United States

Stephenson Cancer Center; 🇺🇸 Oklahoma City, Oklahoma, United States

UT Southwestern; 🇺🇸 Dallas, Texas, United States

Scroll for more (7 remaining)